The FDA has granted Fast Track designation to TEV-53408, an investigational anti-interleukin-15 antibody, for the treatment of celiac disease.

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of ...

The findings of a new study lend support for type 1 diabetes autoantibody screening in people with other autoimmune ...

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a ...

Results from a phase 1 study showed TEV-53408 reduced free serum IL-15 levels in healthy participants. The Food and Drug Administration (FDA) has granted Fast Track designation to TEV-53408, an ...

Celiac disease, traditionally considered an autoimmune disease largely localised in the gastrointestinal tract, is an ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced today that its investigational drug TEV-53408 has received Fast ...

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibodyDesignation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celia ...

If you’re experiencing digestive issues or diarrhea and suspect gluten is the cause, a celiac test could be illuminating, especially if you have a family history of celiac disease. At-home ...

The intestinal T-cell response to a-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. §EMAs detect antibodies to tissue ...